What question did this study set out to answer?

The study aims to examine the role of anti-apoptotic proteins BCL-XL and MCL1 in predicting resistance to venetoclax plus azacitidine in acute myelogenous leukemia.

February 2, 2026PLoS ONEOpen Access

Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia

View Full Paper

Ask AI

Bookmark

Authors

KYKamihara Yusuke KSKikuchi ShoheiNagoya City University NINanako IshikawaUniversity of Toyama

Discussion

Member takes

Implication

Research demonstrates BCL-XL and MCL1 predict resistance to venetoclax plus azacitidine in newly diagnosed acute myelogenous leukemia, suggesting potential for patient stratification.

Key Points

The study aims to examine the role of anti-apoptotic proteins BCL-XL and MCL1 in predicting resistance to venetoclax plus azacitidine in acute myelogenous leukemia.
Analyzed blasts from newly diagnosed AML patients treated with venetoclax plus azacitidine using qPCR.
Confirmed findings using siRNA in cultured cell lines.
Evaluated immunostaining for BCL-XL and MCL1 expression.
High levels of BCL-XL and MCL1 were found in leukemia cells from non-responding patients.
Relapsed patients exhibited increased expression of BCL-XL or MCL1 compared to pre-treatment.
Downregulation of BCL-XL in AML cell lines increased sensitivity to venetoclax.
Immunostaining results correlated with qPCR results, allowing for semi-quantification.

Cite This Study

Yusuke et al. (2026) studied this question.

synapsesocial.com/papers/6980fe35c1c9540dea8100a2 https://doi.org/10.1371/journal.pone.0341461

View Full Paper

Ask AI

Bookmark

Implication

Research demonstrates BCL-XL and MCL1 predict resistance to venetoclax plus azacitidine in newly diagnosed acute myelogenous leukemia, suggesting potential for patient stratification.

Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider